論文 - 詳細
| RRC ID | 37678 |
|---|---|
| 著者 | Takeshita A, Shinjo K, Yamakage N, Ono T, Hirano I, Matsui H, Shigeno K, Nakamura S, Tobita T, Maekawa M, Ohnishi K, Sugimoto Y, Kiyoi H, Naoe T, Ohno R. |
| タイトル | CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. |
| ジャーナル | Br J Haematol |
| Abstract |
The effect of CMC-544, a calicheamicin-conjugated anti-CD22 monoclonal antibody, was analysed in relation to CD22 and P-glycoprotein (P-gp) in B-cell chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) in vitro. The cell lines used were CD22-positive parental Daudi and Raji, and their P-gp positive sublines, Daudi/MDR and Raji/MDR. Cells obtained from 19 patients with B-cell CLL or NHL were also used. The effect of CMC-544 was analysed by viable cell count, morphology, annexin-V staining, and cell cycle distribution. A dose-dependent, selective cytotoxic effect of CMC-544 was observed in cell lines that expressed CD22. CMC-544 was not effective on Daudi/MDR and Raji/MDR cells compared with their parental cells. The MDR modifiers, PSC833 and MS209, restored the cytotoxic effect of CMC-544 in P-gp-expressing sublines. In clinical samples, the cytotoxic effect of CMC-544 was inversely related to the amount of P-gp (P = 0.003), and to intracellular rhodamine-123 accumulation (P < 0.001). On the other hand, the effect positively correlated with the amount of CD22 (P = 0.010). The effect of CMC-544 depends on the levels of CD22 and P-gp. Our findings will help to predict the clinical effectiveness of this drug on these B-cell malignancies, suggesting a beneficial effect with combined use of CMC-544 and MDR modifiers. |
| 巻・号 | 146(1) |
| ページ | 34-43 |
| 公開日 | 2009-6-1 |
| DOI | 10.1111/j.1365-2141.2009.07701.x |
| PII | BJH7701 |
| PMID | 19388933 |
| MeSH | ATP Binding Cassette Transporter, Subfamily B, Member 1 / analysis ATP Binding Cassette Transporter, Subfamily B, Member 1 / antagonists & inhibitors ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism Antibodies, Monoclonal / therapeutic use* Antibodies, Monoclonal, Humanized Antineoplastic Agents / therapeutic use* Cell Count Cell Line, Transformed Cell Line, Tumor Cyclosporins / therapeutic use Dose-Response Relationship, Drug Drug Resistance, Multiple / drug effects Drug Resistance, Neoplasm Flow Cytometry Humans Immunosuppressive Agents / therapeutic use Inotuzumab Ozogamicin Jurkat Cells Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy* Leukemia, Lymphocytic, Chronic, B-Cell / immunology Leukemia, Lymphocytic, Chronic, B-Cell / metabolism Lymphoma, Non-Hodgkin / drug therapy* Lymphoma, Non-Hodgkin / immunology Lymphoma, Non-Hodgkin / metabolism Quinolines / therapeutic use Sialic Acid Binding Ig-like Lectin 2 / analysis Sialic Acid Binding Ig-like Lectin 2 / immunology Treatment Outcome Tumor Cells, Cultured |
| IF | 5.518 |
| 引用数 | 39 |
| WOS 分野 | HEMATOLOGY |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 14 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | K562 Jurkat(RCB0806) |